Bikkavilli Rama Kamesh. / "August 2004." / Thesis (Ph.D.)--Chinese University of Hong Kong, 2004. / Includes bibliographical references (p. 212-223) / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Mode of access: World Wide Web. / Abstracts in English and Chinese.

Thesis (Ph. D.)--University of Florida, 2003. / Title from title page of source document. Includes vita. Includes bibliographical references.

Thesis (Ph. D.)--University of Oklahoma. / Bibliography: leaves 114-126.

Somatostatin (SST) is a peptide hormone that was originally identified in the hypothalamus and subsequently found throughout the central nervous system and in various peripheral organs. Generally classified as an inhibitory factor, SST is secreted by endocrine, neuronal and immune cells and acts to regulate cell secretion, neurotransmission and cell proliferation. There are five receptor-subtypes known to engage SST, termed SSTR1-5, all belonging to the superfamily of G-protein coupled receptors (GPCRs). Within the past few years, there has been a prepondef8:llce of evidence to suggest the importance of GPCR dimerization in receptor-biogenesis, regulation and pharmacology. It has been previously reported in our laboratory, that human (h) SSTR5 homo- and heterodimerizes with hSSTR1 in an agonist-regulated manner. However, it was unclear as to the contribution of each subtype in the formation of the hSSTR1/hSSTR5 heterodimer, the possible molecular determinants involved and the effects of heterodimerization on the pharmacology of the receptors. Furthermore, the dimerization properties of other hSSTRs including their heterodimerization remain undetermined. Here, we demonstrate that agonist binding to hSSTR5 and not hSSTR1 modulates the formation of the heterodimer, with particular emphasis on its carboxyl-terminal tail in specifying the interaction. We also determined the mechanics of the hSSTR2 homodimer, unlike the previous hSSTRs investigated, forms constitutive dimers that dissociate into monomers following activation with agonist. This feature is important for receptor trafficking, as preventing their dissociation impairs agonist-mediated endocytosis. Lastly, we investigated the heterodimerization of hSSTR2 and hSSTR5, an interaction that, like the hSSTR1/hSSTR5 heterodimer, is subtype-specific, requiring selective-activation of hSSTR2 and not hSSTR5. The heterodimer exhibited enhanced signalling characteristics including, prolonged activation of MAP kinases and an increase in the induction of the cyclin-dependent kinase inhibitor p27Kip1. These enhanced properties of the heterodimer conferred an extended growth inhibitory response. Dimerization of GPCRs, with particular emphasis on heterodimers, generates novel receptors with unique properties distinct from those of the individual receptor monomers/homodimers. An understanding on the mechanisms involved in GPCR dimerization could provide a rationale in future drug design.

Thesis (Ph.D.)--University of Tennessee Health Science Center, 2008. / Title from title page screen (viewed on November 5, 2008). Research advisor: Jie Zheng, Ph.D. Document formatted into pages (xiii, 140 p. : ill.). Vita. Abstract. Includes bibliographical references (p. 105-116).

Thesis (Ph. D.)--University of Alabama at Birmingham, 2006. / Title from first page of PDF file (viewed Feb. 19, 2009). Includes bibliographical references.

Thesis (Ph. D.)--University of Washington, 2004. / Vita. Includes bibliographical references (leaves 78-98).

No description available.

Thesis (Ph.D.)--University of Alabama at Birmingham, 2007. / Title from first page of PDF file (viewed on June 25, 2009). Includes bibliographical references.

Thesis (Ph. D.)--Case Western Reserve University, 2006. / [School of Medicine] Department of Biochemistry. Includes bibliographical references. Available online via OhioLINK's ETD Center.